Sourceunknowntext stored

Novo Nordisk's Ziltivekimab Fails to Reduce Cardiovascular Events in Phase 3 ZEUS Trial

Feliza MirasolPublished Jul 31, 2026Original︎ ↗

Claims1

ExaminationsNone

Text198 sections

VersionsOne known

CopiesNone recorded

CorrectionsNone recorded

Facts checked Nov 11, 2026

ReachNo copies recorded

StructureIn 1 claim's map0 sources downstream across 1 claim

EvidenceNot yet read

ReviewsNot reviewed

Examinations

None recorded. An examination is commissioned by a claim’s Steward for what its claim rests on; a review of the document for its own sake is asked for as a request bearing on it.

Text51 passages · 1 marked

No examination yetMarked passage

News0 passages

All News Bio/Pharma News Industry News Supplier News Events0 passages

Multimedia1 passage

Publication0 passages

Conferences0 passages

Conference Listing Latest Conference Content0 passages

More0 passages

Resources1 passage

Webcasts0 passages

Event Calendar0 passages

Subscribe0 passages

My Account0 passages

News0 passages

Multimedia0 passages

Publication0 passages

Conferences0 passages

Resources0 passages

Subscribe0 passages

Webcasts0 passages

Event Calendar0 passages

BioBusiness Partnerships0 passages

Funding and Investments0 passages

Intellectual Property & Patents0 passages

Biologic Drugs in Development0 passages

Mergers and Acquisitions0 passages

BioPharm Products0 passages

BioPharm Sponsored Ad0 passages

Biopharmaceutical Analysis Analytical Best Practices0 passages

Analytical Methods0 passages

Lab Furnishings and Equipment0 passages

Contract Analytical Services0 passages

Finished Product Analysis0 passages

Drug Substance Analysis0 passages

Biopharmaceutical Analysis: GC-MS0 passages

Biopharmaceutical Analysis: Mass Spectrometry0 passages

Biopharmaceutical Analysis: ICP-MS0 passages

Biopharmaceutical Analysis: NMR0 passages

Biopharmaceutical Analysis: Raman0 passages

Biopharmaceutical Analysis: Gas Chromatography0 passages

Biopharmaceutical Analysis: LC-MS0 passages

Biopharmaceutical Analysis: HPLC/UHPLC0 passages

Analytical Instrumentation0 passages

Biosimilars and Biobetters0 passages

Deals, Development and Manufacturing0 passages

Development Formulation0 passages

Process Validation0 passages

Drug Delivery0 passages

Process Development0 passages

Scale Up0 passages

Excipients0 passages

API Synthesis and Manufacturing, Large Molecule0 passages

Formulation and Drug Delivery, Combination Drugs0 passages

Early Phase Development0 passages

Formulation and Drug Delivery, Biologic Drugs0 passages

Formulation and Drug Delivery, Parenterals0 passages

Formulation and Drug Delivery, Specialty Dosage Forms0 passages

Formulation and Drug Delivery, Controlled Release0 passages

Formulation and Drug Delivery, Liquids0 passages

Formulation and Drug Delivery, Solid Dosage0 passages

Formulation and Drug Delivery, Other0 passages

Discovery Pipeline0 passages

Disposables Advisor0 passages

Downstream Processing Viral Clearance0 passages

Manufacturing, Separation and Purification0 passages

Manufacturing Equipment, Downstream Processing0 passages

Manufacturing, Process Chromatography0 passages

Elements of Biopharmaceutical Production0 passages

From the CEO0 passages

From the Editor0 passages

Inside Standards0 passages

Interphex Keynote Sessions0 passages

Manufacturing Manufacturing, Monoclonal Antibodies0 passages

Manufacturing Systems, Single-Use0 passages

Vaccine Development and Manufacturing0 passages

Manufacturing, Aseptic Processing0 passages

Manufacturing, Fill/Finish0 passages

Facility Design and Engineering0 passages

Process Control, Automation, and PAT0 passages

Supply Chain/Logistics0 passages

Manufacturing Best Practices0 passages

Information Technology0 passages

Technology Transfer0 passages

Manufacturing Equipment, Upstream Processing0 passages

Manufacturing Equipment, Biologics0 passages

Cleanroom Equipment and Supplies0 passages

Manufacturing, Parenterals and Injectables0 passages

Clinical Trial Materials0 passages

Manufacturing, Biosimilars and Biobetters0 passages

Manufacturing, Lyophilization0 passages

Manufacturing, Combination Drugs0 passages

Manufacturing, Solid Dosage Drugs0 passages

Manufacturing, Topical Drugs0 passages

Manufacturing, Biologics0 passages

Manufacturing, Specialty Dosage Forms0 passages

Manufacturing, Nucleic Acids0 passages

Manufacturing, Liquid Drug Products0 passages

Manufacturing, Drug Products0 passages

Manufacturing, Cell Therapies0 passages

Manufacturing, Recombinant Proteins0 passages

Manufacturing, Continuous Biologics Processing0 passages

Manufacturing, Gene Therapies0 passages

Packaging, Labeling, and Distribution Systems0 passages

Outsourcing Clinical Trial Services0 passages

Perspectives on Outsourcing0 passages

Contract Services, Regulatory Consulting0 passages

Contract Packaging, Logistics, and Distribution0 passages

Contract Manufacturing, Sterile, Aseptic Processing0 passages

Contract Manufacturing, Biopharmaceutical Production0 passages

Contract Manufacturing, Drug Substance, API0 passages

Contract Manufacturing, Finished Drug Product0 passages

Contract Manufacturing, General0 passages

Contract Services, Formulation and Drug Delivery0 passages

Peer-Reviewed Research0 passages

Pharmacopoeial Compliance Series0 passages

Quality/GMPs Ask the Expert0 passages

Regulatory/GMP Compliance0 passages

Compliance Notes0 passages

Regulatory Beat0 passages

European Regulatory Watch0 passages

Adverse Events and Recalls0 passages

Regulatory/GMP Compliance, Europe0 passages

Regulatory/GMP Compliance, Emerging Markets0 passages

Audits and Inspections0 passages

Anticounterfeiting, Track and Trace Systems0 passages

Quality by Design0 passages

Compendial Compliance1 passage

Quality Control/Quality Assurance0 passages

Regulatory Filings and Submissions0 passages

Regulatory Authority Actions0 passages

Therapeutic Specific Areas0 passages

Upstream Processing Manufacturing, Cell-Line Selection0 passages

Manufacturing, Expression Systems0 passages

Manufacturing, Cell Culture and Fermentation0 passages

Viewpoints0 passages

Weighing Up Big Pharma0 passages

Choose Topic Spotlight - Analytics |0 passages

Development |0 passages

Downstream Processing |0 passages

Manufacturing |0 passages

Outsourcing |0 passages

Quality/GMPs |0 passages

Upstream Processing0 passages

Advertisement0 passages

News | Articles | July 31, 20261 passage

Author(s) Feliza Mirasol0 passages

Listen 0:00 / 0:000 passages

Key Takeaways5 passages · 1 marked

Clinical efficacy was null (HR 0.99; 95% CI 0.88-1.11) even though free IL-6 and hsCRP fell, underscoring biomarker–outcome dissociation for IL-6 inhibition.

The IL-6 inhibitor ziltivekimab did not reduce cardiovascular events in the ZEUS trialVerified

Not yet read by this claim’s Steward.

SHOW MORE1 passage

Advertisement3 passages

Key facts1 passage

Trial enrolled >6300 people with ASCVD, CKD, and inflammation0 passages

Ziltivekimab confirmed IL-6 pathway engagement despite no MACE benefit0 passages

Higher serious infection rate with ziltivekimab; no mortality difference0 passages

HERMES and ARTEMIS trials continue, readout expected 1H 20270 passages

Non-cash impairment charge expected in Q3 2026; 2026 profit outlook unaffected11 passages

References2 references

Advertisement0 passages

Development1 passage

BioBusiness1 passage

Biologic Drugs in Development1 passage

Clinical Trial Materials1 passage

Manufacturing0 passages

Lineage across 1 claim

Draws on · none recorded

This source

Novo Nordisk's Ziltivekimab Fails to Reduce Cardiovascular Events in Phase 3 ZEUS Trial

in 1 claim's map

Drawn on by · none recorded

Record

Kind: unknown
Authors: Feliza Mirasol
Publisher: Not recorded
Published: Jul 31, 2026
DOI: None
Link: https://www.biopharminternational.com/view/novo-nordisk-ziltivekimab-zeus-phase-3-cardiovascular
Archived copy: None found
Stored text: 13,853 characters, retrieved Nov 11, 2026 · 198 sections, 51 passages
Claims extracted: Not recorded
Versions: One known
Copies: None recorded
Corrections: None recorded
Facts checked: Nov 11, 2026

History 3

Nov 11, 2026DividedSegmenter · Divided into 249 parts by its own structure
Nov 11, 2026FactsFacts fetcher · Facts looked up
Nov 11, 2026Entered the graphEntered the graph; copy stored